Trials / Completed
CompletedNCT03921203
ApoB48 Metabolism in Plasma and Interstitial Fluid
ApoB48IC2 Metabolism in Plasma and Interstitial Fluid
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Postprandial increases in the levels of atherogenic chylomicron remnant lipoprotein particles have long been considered a presumable risk factor for the development of atherosclerosis with time, also in normolipidemic subjects. apoB-48 (Chylomicron) in blood is a specific marker for intestinal derived lipoproteins. Specific aim: To determine if apoB-48 containing lipoproteins may appear in IC in the postprandial state after a standard meal and investigate the effect fasting and feeding have on levels of lipids, apolipoproteins and the cholesterol component of lipoproteins in IF and plasma. Methodology: Intercellular fluid will be collected using the cup technique. IF will be collected in intervals corresponding to different periods after food intake. The IF from these different occasions will then be analysed and compared using FPLC and Elisa.
Conditions
Timeline
- Start date
- 2019-04-17
- Primary completion
- 2021-12-01
- Completion
- 2022-12-31
- First posted
- 2019-04-19
- Last updated
- 2023-02-27
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03921203. Inclusion in this directory is not an endorsement.